1 completed, 1 not yet recruiting, 1 recruiting. 2 Phase 3, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 2 | Completed 1, Recruiting 1 |
| Phase 2 | 1 | Not yet recruiting 1 |
Follow Nemolizumab 30 mg: new trials by email Literature Review of Nemolizumab 30 mg trials Research Report on Nemolizumab 30 mg
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Randomized, Double-blind, Placebo-controlled Study of Nemolizumab in Chinese Subjects With Moderate-to-severe Atopic Dermatitis Nemolizumab 30 mg, Placebo - Atopic Dermatitis | Phase 3 | Recruiting | Galderma R&D | 240 | 2026-10-08 | 2026-10-16 |
| Nemolizumab for LS Nemolizumab 30 mg - Lichen Sclerosus of Vulva | Phase 2 | Not yet recruiting | University of Texas Southwestern Medical Center | 25 | 2026-09-01 | 2026-07-15 |
| Study to Assess the Efficacy and Safety of Nemolizumab (CD14152) in Participants With Prurigo Nodularis (PN) Nemolizumab 30 mg, Placebo - Prurigo Nodularis | Phase 3 | Completed | Galderma R&D | 286 | 2020-09-11 | 2024-07-10 |
Dermatitis, Atopic (1) · Lichen Sclerosus et Atrophicus (1) · Neurodermatitis (1) · Prurigo (1) · Pruritus (1) · Skin Diseases (1) · Vulvar Lichen Sclerosus (1)
Galderma R&D (2) · University of Texas Southwestern Medical Center (1)
United States (2) · Austria (1) · Canada (1) · China (1) · Denmark (1) · Germany (1) · Hungary (1) · Italy (1) · Poland (1) · Sweden (1) · United Kingdom (1)
PMID 37888917, PMID 39602139, PMID 40266487
2019 (1)